The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...
Two decades ago, Professor Shao-Cong Sun first discovered the non-canonical NF-κB pathway mediated by NF-κB-inducing kinase (NIK). Since then, more ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from ...
Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
RUN | Powered by Outside on MSN
Ultrarunning damages cells as much as a severe infection—that might actually be a good thing
A new study shows that ultramarathons damage and replenish red blood cells in ways that could help treat cancer patients.
Learn more about whether Halozyme Therapeutics, Inc. or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Explore new findings on ovarian cancer and how blocking focal adhesion kinase can enhance immune response in treatment.
TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results